← Evidence map

ReviewReviews in endocrine & metabolic disorders2026

Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Roberto Vettor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). | Socratic